ArticleBlood advances2026
Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
abstractLittle is known about the long-term health and well-being of older (≥60 years) patients who received blood or marrow transplant (BMT), a growing population at risk for late-occurring morbidity and mortality. This study included ≥2-year survivors (N=1581) who underwent BMT between 1990 and 2014 at age ≥60 years. Severe/life-threatening and fatal chronic health conditions were identified using Common Terminology Criteria for Adverse Events. Multivariable regression analysis compared the risk of severe/life-threatening health conditions and health status between survivors and 594 age-matched sibling controls. Standardized mortality ratios (SMRs) and, for subsequent malignant neoplasms, standardized incidence ratios (SIRs) were calculated and compared with the general population. The prevalence of severe/life-threatening conditions was 72% in survivors of BMT vs 51% in siblings (P< .001), yielding 2.9-fold higher odds of severe/life-threatening conditions (95% confidence interval [CI], 2.2-3.7) among the survivors. Survivors were more likely to report poor general health (odds ratio [OR], 4.1 [95%CI, 2.8-6.0]), functional impairment (OR, 3.2 [95%CI, 2.5-4.0]), activity limitation (OR, 3.1 [95%CI, 2.4-3.9]), and frailty (OR, 3.5 [95% CI, 2.1-6.0]). Among survivors, the overall SMR was 5.3 (95%CI, 5.0-5.6). There was an especially high risk of infection-related mortality (SMR=35.2 [95%CI, 30.3-40.6]). Survivors had a 3.8-fold risk of subsequent neoplasms (95%CI, 3.5-4.2) relative to the general population, with incidence rates highest for Hodgkin lymphoma (SIR=18.5 [95%CI, 7.4-37.5]) and melanoma (SIR=7.4 [95%CI, 5.1-10.2]). Older recipients of BMT have a high burden of severe/life-threatening conditions and poor health status compared with sibling controls, contributing to increased relative risk of premature mortality. These findings emphasize the ongoing health care burden of survivors of BMT, particularly in this older population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.